On Jan. 21, 2021, Zoetis announced it had as expanded its line of recombinant vector vaccines with the launch of Poulvac^® Procerta™ HVT-IBD, which provides early protection against the contemporary infectious bursal disease (IBD) viruses confronting U.S. broilers.

In challenge studies, Poulvac Procerta HVT-IBD administered in ovo provided 78% protection at 14 days of age against the AL2 variant, which now accounts for half of the IBD viruses circulating among U.S. broiler flocks. The Zoetis team also conducted two separate studies to test the in ovo efficacy of Poulvac Procerta HVT-IBD against a classic virulent IBD challenge on day 14 of age. The new vaccine provided 96% protection.